1.0Innovations- und Gründerzentrum Biotechnologie IZBhttps://www.izb-online.de/en/Strong business year for Morphosysrich600338<blockquote class="wp-embedded-content" data-secret="ckgn5NXu1P"><a href="https://www.izb-online.de/en/2687/">Strong business year for Morphosys</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.izb-online.de/en/2687/embed/#?secret=ckgn5NXu1P" width="600" height="338" title="“Strong business year for Morphosys” — Innovations- und Gründerzentrum Biotechnologie IZB" data-secret="ckgn5NXu1P" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://www.izb-online.de/wp-includes/js/wp-embed.min.js
</script>
https://www.izb-online.de/wp-content/uploads/2020/03/Bild-1_MorphoSys-Gebäude.jpg20001098”2016 was a successful year for Morphosys. We applied for market approval through our pharmaceutical partner Janssen for the first therapeutic antibody based on our technology. We expect to hear the decision on the approval of Guselkumab in the second half of 2017,” said Morphosys CEO Dr. Simon Moroney, commenting on the successful business year 2016.